

Jeffrey (Jeff) Kawalek

Jeffrey (Jeff) Kawalek joined Zambon USA Ltd. as Chief Compliance Officer, U.S in 2023. He previously served as Deputy Chief Compliance Officer, U.S. at Jazz Pharmaceuticals, Inc. where he oversaw the day-to-day operations for all aspects of the company's compliance program and Corporate Integrity Agreement (CIA). Preceding Jazz, Jeff held a similar role at Ipsen Biopharmaceuticals, Inc. Prior, he spent nearly ten years at Novo Nordisk, Inc. and as the first compliance department hire, supported the development and implementation of Novo Nordisk's U.S. Compliance Program and helped to set the vision, strategy, and direction of the program.

Jeff's entry into pharmaceutical compliance began nearly twenty-five years ago when he worked as a consultant and provided litigation support services related to the Medicaid Drug Rebate Program, conducted pharmaceutical healthcare compliance risk assessments, and assisted small, mid-size, and large pharmaceutical companies to develop and operationalize compliance and ethics programs and solutions to comply with existing and emerging U.S. laws and industry guidelines.

Jeff holds a Bachelor of Science in Business Administration from the University of Delaware and an MBA from Temple University Fox School of Business and Management. He is an active member of the Pharmaceutical Compliance Forum [PCF] and has completed two terms on the Board, serving first as Board Secretary (2015-2017) then Board Chair (2017-2021).